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Thao-Ly Phan,1 Jobayer Hossain,2
Stephen Lawless,3 and Lloyd Neil Werk4

OBJECTIVE

To evaluate the association between the frequency of visits and glycated hemoglobin (GHb) measurements on glycemic control in youth with type 1 diabetes.
RESEARCH DESIGN AND METHODS

A retrospective longitudinal cohort study of 1,449 youth with type 1 diabetes
(mean age 11.4 years, 50% female, 74% Caucasian, 24% with Medicaid) followed at
ﬁve pediatric endocrinology clinics from the years 2008–2011 was conducted. By
hierarchical cluster analysis, three homogeneous groups of patients were generated: those with a relative increase in GHb (worsened [n = 237]), no change in GHb
(stable [n = 842]), and a decrease in GHb (improved [n = 370]) over the study
period. The number of visits and GHb measurements per year were compared
among the three groups by multinomial logistic regression analysis using one visit
or GHb test per year as a reference and controlling for patient demographic and
baseline characteristics.
RESULTS

Patients with quarterly visits were least likely to have worsened glycemic control
(odds ratio 0.33, P , 0.05) and were most likely to have improved glycemic control
(3.48, P , 0.01). Patients with four GHb tests a year (0.53, P , 0.05) were least
likely to have worsened glycemic control.
CONCLUSIONS

Quarterly visits and GHb testing are associated with glycemic control in youth with
type 1 diabetes.
Diabetes Care 2014;37:341–345 | DOI: 10.2337/dc13-0980

Optimal glycemic control is associated with a reduction in the risk for complications
associated with diabetes (1–3). However, glycemic control remains suboptimal in
many youth with type 1 diabetes (4–7). The American Diabetes Association
proposed guidelines recommending visits with a health care provider and
glycated hemoglobin (GHb) testing at least two times a year for patients with good
glycemic control and quarterly for patients with poor glycemic control (8,9), presuming
that close monitoring improves management and reduces complications.
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Visit Frequency and Glycemic Control

Despite the perceived value of routinely
monitoring GHb, the importance of GHb
testing at regular intervals has not been
well described in youth and has been
documented in only one adult study
(10). Studies in adults have
demonstrated the important role of
frequent visits in achieving glycemic
control (11,12), a ﬁnding supported by
one study in youth with type 1 diabetes
that found improved glycemic control in
those who had three or four visits per
year compared with those who had only
one or two (13). The frequency of visits
and GHb testing is determined by
provider preference but can also be
inﬂuenced by patient treatment
adherence, with higher rates of
nonadherence described in patients of
lower socioeconomic status, singleparent households, and minority race
(13–15).
Determination of the optimal number of
visits and GHb testing in youth with type
1 diabetes to optimize glycemic control
may inform the practice of costeffective medicine. Furthermore,
adoption of different management
schedules may be more effective for
patient subgroups according to baseline
characteristics. In the present study, we
examined the relationship between
frequency of visits and GHb testing on
glycemic control in youth with type 1
diabetes.
RESEARCH DESIGN AND METHODS

The dataset from a retrospective cohort
study was extracted from the electronic
medical record (EMR). This longitudinal
study used deidentiﬁed records
extending from July 2008 to June 2011
and was approved by the Nemours
Institutional Review Board.
Patients were included in the study if
they were seen at any of ﬁve Nemours
pediatric endocrinology clinics
(Jacksonville, Orlando, and Pensacola,
FL; Philadelphia, PA; and Wilmington,
DE) during the ﬁrst two ﬁscal quarters of
2008 and had a previous diagnosis of
type 1 diabetes identiﬁed on their
problem list. Scheduled visits with an
endocrinology provider (visit) were
recorded in and extracted from the
EMR. No routine scheduling protocols
were used at any of the practices.
Patients were excluded from the study if
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they had only one visit, had a single GHb
test, or were followed for ,1 year.
Demographics, including age, sex, race,
practice location, and insurance status,
were obtained from the EMR.
GHb Measurement

GHb measurements were obtained at
the discretion of the provider. Each site
was internally consistent, using the
same device to provide a point of care
(POC) GHb assay. The same type of POC
GHb device (Siemens DCA Vantage
Analyzer) was used at all sites. The
detection range with this device for the
GHb assay is 2.5–14% (4–130 mmol/
mol), with a reference range of 4.4–6.4%
(25–46 mmol/mol). GHb values .14%
were unable to be quantiﬁed and, thus,
were coded as 14% in the dataset. The
standard operating procedure at each
site was to collect blood samples for
POC testing at the time of the ofﬁce visit,
but GHb from external laboratory
specimens were also included if
available. The DCA Vantage Analyzer has
acceptable precision (16).
Statistical Analysis

The number of visits and GHb tests per
year were calculated and served as the
primary independent variables. The
number of ﬁscal quarters in a year with
visits and GHb tests obtained were
calculated and served as secondary
independent variables. We used a
mixed-effects model (17) to
characterize the individual- and
population-level changes in GHb over
time and with visit frequency. Change
from baseline GHb was used as the
response variable, and patient
demographic variables, baseline GHb,
and time from study entry were used as
ﬁxed-effects variables in the model. The
intercept and visit frequencies were
used as random effects in the model to
capture the pattern of individual-level
changes in GHb over visit frequencies.
A hierarchical cluster analysis of random
effects (17,18) was performed to group
patients by homogeneous patterns of
glycemic control. The cluster analysis
identiﬁed the following three distinct
and signiﬁcantly different group
patterns of change in GHb per year (P ,
0.001): a relative increase (worsened
glycemic control), no change (stable
glycemic control), or a decrease

(improved glycemic control) in GHb over
the study period. Study variables,
including demographics, baseline
characteristics, and the independent
variables of visit and GHb testing
frequency, were compared among the
three groups.
Quantitative variables are presented as
mean (SD). Categorical variables are
presented as frequencies and
percentages. Multivariable multinomial
logistic regression analyses were
performed to explore the association
of study variables with glycemic control
groups. The adjusted odds ratios (ORs)
with P values are presented in the text,
with CIs also presented in the tables.
Model assumptions were veriﬁed
before analyses. All tests were two
tailed at the 0.05 level of signiﬁcance.
SAS (SAS Institute, Cary, NC) and SPSS
(IBM Corporation, Chicago, IL) statistical
software programs were used for the
analyses.

RESULTS
Categorization of Patients on the
Basis of Change in GHb

Mean GHb in the cohort remained
relatively stable over the study period,
increasing slightly from 8.3% (SD 1.5%)
(67 mmol/mol) during the initial year
of study to 8.5% (1.4%) (69 mmol/mol)
during the last year of study. Table 1
shows the GHb trends over the study
period for the three groups of glycemic
control generated by the hierarchical
cluster analysis: worsened (n = 237),
stable (n = 842), and improved
(n = 370).
Patient Characteristics

There were 1,449 patients included in
the study (Table 2). The mean age was
11.4 (SD 3.3) years. There were an equal
proportion of males and females. The
majority of patients were Caucasian
(74%) and had commercial insurance
(67%). Patients who were African
American (OR 1.78, P , 0.01), had
Medicaid insurance (1.51, P , 0.01), or
were older (F = 1.11, P , 0.001) were
more likely to have worsened glycemic
control (Table 2). Patients with higher
baseline GHb were more likely to
have improved glycemic control (F = 1.43,
P , 0.001).
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Relationship Between Glycemic
Control and Frequency of GHb Testing

Table 1—Mean patient GHb over time by glycemic control group
GHb
Glycemic control
Year

All patients

Worsened

Stable

Improved

2008
%
mmol/mol
n
2009
%
mmol/mol
n

8.3 (0.03)
66.8 (0.27)
1,449

8.8 (0.07)
72.8 (0.77)
237

8.1 (0.03)
64.8 (0.31)
842

8.3 (0.06)
67.6 (0.63)
370

8.4 (0.02)
68.5 (0.24)
1,419

9.8 (0.06)
83.6 (0.67)
230

8.3 (0.02)
66.8 (0.25)
832

7.9 (0.04)
62.3 (0.44)
357

2010
%
mmol/mol
n

8.4 (0.02)
68.8 (0.25)
1,359

10.1 (0.06)
86.9 (0.70)
213

8.3 (0.02)
67.2 (0.26)
798

7.8 (0.04)
61.2 (0.41)
348

2011
%
mmol/mol
n

8.5 (0.03)
69.9 (0.38)
1,094

10.2 (0.10)
88.1 (1.07)
160

8.4 (0.04)
68.2 (0.39)
649

7.9 (0.06)
63.1 (0.65)
285

Data are mean (SD) unless otherwise indicated.

Relationship Between Glycemic
Control and Ofﬁce Visit Frequency

On average, patients had 3.2 (SD 1.1,
range 1–11) visits per year and 2.9
(0.7) ﬁscal quarters with visits per
year. Table 3 compares groups on the
basis of visit frequency, with the
reference group being patients with
one visit or one ﬁscal quarter with
visits per year and adjusting for
demographic and baseline

characteristics. Patients with four
visits per year (OR 0.36, P , 0.05) or
quarterly visits (0.33, P , 0.05) were
least likely to have worsened glycemic
control. Patients with quarterly visits
were also most likely to have improved
glycemic control (3.48, P , 0.01). In
multivariable regression analysis, race
(P , 0.005), insurance status (P ,
0.01), and initial age (P , 0.05) had
signiﬁcant effects on visit frequency.

On average, patients had 3.0 (SD 1.0,
range 1–10) GHb tests per year and 2.8
(0.7) ﬁscal quarters in a year with a GHb
test. Table 3 compares groups on the
basis of GHb testing frequency, with
the reference group being patients
with one GHb test per year or one ﬁscal
quarter per year with a GHb obtained
and adjusting for demographic and
baseline characteristics. Patients with
four GHb tests per year were least
likely to have worsened glycemic
control (OR 0.53, P , 0.05), and
patients with more than ﬁve GHb tests
per year were least likely to have
improved glycemic control (0.28, P ,
0.01). In multivariable regression
analysis, race (P , 0.01), insurance
status (P , 0.05), and initial age (P ,
0.05) had signiﬁcant effects on
frequency of GHb testing.
Characterization of Patients With
More Than Five Ofﬁce Visits per Year

A small percentage (7.9%) of patients
had ﬁve or more visits per year (mean
5.7 [SD 1.3], range 5–11). These patients
were more likely to have a higher
baseline GHb (F = 1.15, P , 0.05), have
Medicaid (OR 2.13, P , 0.001), or be
non-Hispanic (2.94, P , 0.05) and were
less likely to have improved glycemic
control (0.31, P , 0.001).

Table 2—Comparison of glycemic control groups on the basis of patient characteristics
Glycemic control
All patients
(n = 1,449)

Improved
(n = 370)

Stable
(n = 842)

F or adjusted OR (CI) for glycemic control
Worsened
(n = 237)

Worsened†‡

Improved‡§

0.93

1.43***

12.2 (2.7)

1.11***

0.93***

424 (58.6)
418 (57.6)

125 (17.3)
112 (15.4)

Reference
0.88 (0.66–1.17)

Reference
1.05 (0.82–1.35)

265 (24.6)
41 (25.5)
43 (29.1)
21 (32.8)

653 (60.7)
81 (50.3)
76 (51.4)
32 (50)

158 (14.7)
39 (24.2)
29 (19.6)
11 (17.2)

Reference
1.78** (1.17–2.72)
1.41 (0.89–2.23)
1.34 (0.67–2.67)

Reference
0.71 (0.47–1.01)
0.97 (0.65–1.45)
1.18 (0.66–2.09)

238 (24.5)
104 (30.1)
28 (21.4)

594 (61.1)
169 (48.8)
79 (60.3)

140 (14.4)
73 (21.1)
24 (18.3)

Reference
1.51* (1.08–2.11)
1.15 (0.70–1.87)

Reference
0.91 (0.58–1.44)
1.08 (0.80–1.46)

Baseline GHb, mean (SD)
%
mmol/mol

8.3 (1.5)
66.8 (16.6)

8.8 (1.8)
73.1 (19.9)

8.0 (1.3)
64.1 (14.4)

8.3 (1.4)
66.7 (15.4)

Age (years), mean (SD)

11.4 (3.3)

11.0 (3.6)

11.4 (3.3)

Sex
Male
Female

726 (50.1)
723 (49.9)

174 (24.1)
196 (27.0)

1,076 (74.3)
161 (11.1)
148 (10.2)
64 (4.4)
972 (67.1)
346 (23.9)
131 (9.0)

Race/ethnicity
Caucasian
African American
Hispanic
Other
Insurance
Commercial
Medicaid
Other

Data are mean (SD) or n (%) unless otherwise indicated. *P , 0.05. **P , 0.01. ***P , 0.001. †Compared with groups with stable or improved
glycemic control. ‡Controlling for remainder of patient characteristics. §Compared with group with stable or worsened glycemic control.
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Table 3—Comparison of glycemic control groups on the basis of visit and laboratory frequency
Glycemic control

Adjusted OR (CI) for glycemic control

All patients

Improved

Stable

Worsened

Worsened†‡

Improved‡§

34 (2.3)
214 (14.8)
527 (39.5)
515 (35.5)
114 (7.9)

11 (32.4)
81 (37.9)
150 (26.2)
113 (21.9)
15 (13.2)

13 (38.2)
98 (45.8)
323 (56.5)
336 (65.2)
72 (63.2)

10 (29.4)
35 (16.4)
99 (17.3)
66 (12.8)
27 (23.7)

Reference
0.46 (0.20–1.07)
0.51 (0.23–1.12)
0.36 (0.16–0.81)*
0.71 (0.29–1.70)

Reference
1.45 (0.65–3.26)
0.87 (0.40–1.90)
0.75 (0.34–1.65)
0.33 (0.13–0.85)

58 (4.0)
300 (20.7)
745 (51.4)
346 (23.9)

16 (27.6)
90 (30.0)
188 (25.2)
76 (22.0)

27 (46.6)
150 (50.0)
440 (59)
225 (65.0)

15 (25.9)
60 (20.0)
117 (15.7)
45 (13.0)

Reference
0.95 (0.37–1.91)
0.56 (0.23–1.35)
0.33 (0.12–0.90)*

Reference
1.54 (0.70–3.39)
2.32 (1.00–5.41)
3.48 (1.38–8.76)**

GHb per year
1 (n = 65)
2 (n = 309)
3 (n = 686)
4 (n = 301)
$5 (n = 88)

65 (4.5)
309 (21.3)
686 (47.3)
301 (20.8)
88 (6.1)

20 (30.8)
111 (35.9)
157 (22.9)
71 (23.6)
10 (11.4)

29 (44.6)
153 (49.5)
412 (60.1)
191 (63.5)
55 (62.5)

16 (24.6)
45 (14.6)
117 (17.1)
39 (13)
23 (26.1)

Reference
0.58 (0.30–1.12)
0.74 (0.40–1.36)
0.53 (0.27–1.03)*
0.96 (0.44–2.01)

Reference
1.26 (0.68–2.31)
0.69 (0.38–1.24)
0.79 (0.42–1.47)
0.28 (0.12–0.65)**

Quarters per year with GHb obtained¶
1 (n = 75)
2 (n = 366)
3 (n = 730)
4 (n = 278)

75 (5.2)
366 (25.3)
750 (50.4)
278 (19.2)

21 (28)
120 (32.3)
166 (22.7)
63 (22.7)

37 (49.3)
181 (49.5)
441 (60.4)
183 (65.8)

17 (22.7)
65 (17.8)
123 (16.8)
32 (11.5)

Reference
5.84 (0.61–55.81)
2.21 (0.24–20.08)
0.97 (0.11–8.75)

Reference
2.26 (0.25–20.73)
4.74 (0.47–47.52)
7.18 (0.68–76.47)

Visits per year
1 (n = 34)
2 (n = 214)
3 (n = 572)
4 (n = 515)
$5 (n = 114)
Quarters per year with visits||
1 (n = 58)
2 (n = 300)
3 (n = 745)
4 (n = 346)

Data are n (%) unless otherwise indicated. *P , 0.05. **P , 0.01. †Compared with group with stable or improved glycemic control. ‡Controlling for
age, sex, race, insurance status, and baseline GHb. §Compared with group with stable or worsened glycemic control. ||OR also controlling for
absolute number of visits per year. ¶OR also controlling for absolute number of GHb tests per year.

CONCLUSIONS

Consistent with prior studies (14,15),
this longitudinal cohort study of 1,449
youth with type 1 diabetes supports the
importance of routine visits and GHb
testing in this population. The ﬁndings
suggest that quarterly visits and GHb
monitoring may prevent worsening
glycemic control in youth with type 1
diabetes. These ﬁndings were present
even when adjusting for factors known
to affect glycemic control and treatment
adherence, including race, insurance
status, age, and baseline GHb. It is likely
that patients with less frequent visits or
GHb testing may miss opportunities to
receive education, support, and changes
to treatment regimens to promote
glycemic control (11,19).
Patients with worsened glycemic
control over the study period had lower
baseline GHb than patients with stable
and improved glycemic control.
Although this may represent a
regression of GHb values to the mean,
the associations between visit and
laboratory frequency with glycemic
control were signiﬁcant even after

adjusting for baseline GHb. We also
found that patients of African American
race, with Medicaid, or of older age
were more likely to have worsened
glycemic control, ﬁndings consistent
with other studies (13–15,19–22).
These subgroups had fewer visits and
GHb tests, which may explain their
increased likelihood for worsened
glycemic control.
A subgroup of patients required more
than four visits a year and demonstrated
worsened glycemic control. It is likely
that these patients represent a need for
more frequent follow-up and
monitoring because of their poor
glycemic control, as demonstrated by
their higher baseline GHb. Of note,
these patients were more likely to have
Medicaid, which may be a proxy for low
socioeconomic status and has been
associated with poor glycemic control in
prior studies (13–15,20,21).
Because this was a retrospective study
using primarily administrative data and
laboratory results previously recorded
in our EMR, several limitations should
be noted. We were unable to account

for certain factors that may have
inﬂuenced glycemic control, including
interventions other than visits with
endocrinology physicians and nurse
practitioners, duration of diabetes
diagnosis, type of insulin regimen used,
maturation (Tanner stage), and GHb
device used (whether with a POC device
or at an external laboratory). We also
were unable to account for certain
factors that may have inﬂuenced visit
frequency, such as provider preference,
which may have been inﬂuenced by
glycemic control, patient motivation
and adherence, and other
socioeconomic variables beyond
insurance status. Future studies should
examine the role of these factors on visit
and GHb testing frequency in addition to
glycemic control.
In summary, quarterly visits and GHb
testing are associated with glycemic
control in youth with type 1 diabetes.
Certain patient subgroups have less
frequent visits and GHb testing and may
require increased support to ensure
adherence to visit and GHb testing
recommendations.
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